

EPO declares intention to approve ICOp^{re}® patent application

Iconovo AB today announced that The European Patent Office (EPO) declares its intention to approve Iconovos patent application for the inhaler platform ICOp^{re}® (Communication under Rule 71(3) EPC). The patent describes the proprietary design of dose-administering in Iconovos ICOp^{re}® inhaler, which is deemed inter-changeable for GSKs Ellipta® inhaler. The patent is also pending approval in USA and China.

ICOp^{re}® is Iconovo's most advanced inhaler, developed for global regulatory approval as a substitutable generic alternative to GSK's Ellipta®. As previously announced, Iconovo has received positive guidance from the U.S. Food and Drug Administration regarding generic substitutability and the potential for AB rating.

ICOp^{re}® is pre-metered and pre-filled with 30 individually sealed doses and features a two-compartment system, a precise dose counter. It is designed to support mono, dual, or triple-combination products. The inhaler is intuitive and easy to use, operating in three simple steps: open, inhale, and close.

ICOp^{re}® targets a market with approximately USD 6 billion in annual sales.

ICOp^{re}® is currently available for late-stage development and commercialization partnerships.

"This patent protects a unique property of ICOp^{re}®, differentiating the inhaler from technologies using blister strips", says Magnus Waldt, Senior Technical Lead at Iconovo. "This patent will further strengthen the attractiveness of the ICOp^{re}® inhaler and as such it will enhance our efforts to partner the product for late-stage development and commercialization", says Anders Månsson, CEO of Iconovo.

Contact:

Anders Månsson, CEO, Iconovo AB
Anders.mansson@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Tapper Partners AB.

Contacts

Anders Månsson, CEO

+46 76 518 8491

anders.mansson@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Tapper Partners AB.

Attachments

[EPO declares intention to approve ICOpres® patent application](#)